|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8220 EUR | +17.09% |
|
+54.80% | -46.48% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 64.85M | |
| 2.64% | 2.76% | 75.66x | 7.17x | 5.3x | 22.45x | 29.48x | 317B | |
| 1.61% | 1.68% | 24.65x | 2.08x | 3.35x | 11.83x | 19.88x | 72.79B | |
| 2.85% | 2.99% | 15.88x | 1.37x | 1.99x | 6.76x | 8.16x | 8.16B | |
| -.--% | -.--% | 21.7x | 5.73x | 6.23x | 17.18x | 17.95x | 4.51B | |
| 0.75% | 0.76% | 36.88x | 2.41x | 2.35x | 27.49x | 42.15x | 3.94B | |
| -.--% | -.--% | -146.59x | - | - | - | - | 2.73B | |
| 4.35% | 3.69% | 14.22x | 0.82x | 1.05x | 7.64x | 26.1x | 1.03B | |
| Average | 1.74% | 1.7% | 6.06x | 3.26x | 3.38x | 15.56x | 23.95x | 51.27B | |
| Weighted average by Cap. | 2.41% | 2.51% | 62.82x | 6.07x | 4.85x | 20.19x | 27.32x |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
